PAVmed (PAVM) Return on Capital Employed (2016 - 2025)
PAVmed's (PAVM) quarterly Return on Capital Employed came in at 92.39% in Q4 2025, down 74146.0% year-on-year from N/an in Q4 2024, and down 39.66% quarter-over-quarter from 66.16% in Q3 2025.
PAVmed (PAVM) Return on Capital Employed (2016 - 2025) Analysis & Trends
PAVmed's Return on Capital Employed history runs 10 years deep, the most recent figure standing at 92.39% for Q4 2025.
- On a quarterly basis, Return on Capital Employed fell 74146.0% year-over-year to 92.39% in Q4 2025; TTM through Dec 2025 was 92.39%, a 74146.0% decrease from a year earlier, with the FY2025 full-year figure at 109.58%, down 136045.0% from the prior year.
- Return on Capital Employed retreated to 92.39% in Q4 2025 per PAVM's latest filing, from 66.16% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 1157.5% in Q3 2023 and bottomed at 1010.82% in Q1 2023.
- The 5-year median for Return on Capital Employed is 93.56% (2025), against an average of 26.81%.
- Biggest YoY gain for Return on Capital Employed was 139988 bps in 2023; the steepest drop was 91406 bps in 2023.
- Year by year, Return on Capital Employed stood at 94.73% in 2021, then slumped by 337 bps to 413.61% in 2022, then jumped by 200 bps to 414.25% in 2023, then soared by 57 bps to 649.07% in 2024, then sank by 114 bps to 92.39% in 2025.
- Per Business Quant, the three latest PAVM Return on Capital Employed figures stand at 92.39% (Q4 2025), 66.16% (Q3 2025), and 76.7% (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 24.24% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 8.38% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.30% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | PAVmed | 9.85 Mn | -3.35 Mn | -4,000.00 | -92.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -92.39% |
| Sep 30, 2025 | -66.16% |
| Jun 30, 2025 | -76.70% |
| Mar 31, 2025 | -120.00% |
| Dec 31, 2024 | 649.07% |
| Jun 30, 2024 | 396.05% |
| Mar 31, 2024 | 314.85% |
| Dec 31, 2023 | 414.25% |
| Sep 30, 2023 | 1,157.50% |
| Jun 30, 2023 | -975.38% |
| Mar 31, 2023 | -1,010.82% |
| Dec 31, 2022 | -413.61% |
| Sep 30, 2022 | -242.39% |
| Jun 30, 2022 | -171.73% |
| Mar 31, 2022 | -96.76% |
| Dec 31, 2021 | -94.73% |
| Sep 30, 2020 | 131.74% |
| Jun 30, 2020 | 150.34% |
| Dec 31, 2019 | 236.08% |
| Dec 31, 2018 | 521.57% |